Resverlogix and Hepalink Start Taiwan/China Trial of CVD/Diabetes Treatment Jul 11, 2017 Life Science
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial Jul 11, 2017 Life Science
Google Invests Undisclosed Sum Into Boston’s Decibel And Its Hearing Loss R&D Program Jul 6, 2017 Life Science
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) is a Technology Disruptor for Edible Cannabinoids Jul 6, 2017 Life Science
BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer Jul 6, 2017 Life Science
DelMar Pharmaceuticals Joins National Brain Tumor Society’s Research Roundtable Jun 30, 2017 Life Science
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone Jun 29, 2017 Life Science
DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM Jun 23, 2017 Life Science
Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL 453 in China Jun 22, 2017 Life Science
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma (“GBM”) at SNO’s Pediatric Neuro-Oncology Basic and Translational Research Conference Jun 17, 2017 Life Science
